Uganda is on track in the fight against HIV/AIDS, with efforts enhanced by the rollout of long-acting Cabotegravir (LA-CAB).
In 2024, the Uganda AIDS Commission announced the introduction of long-acting Cabotegravir (CAB-LA), an injectable PrEP option with 99% efficacy, following approval by the National Drug Authority. This marks a major milestone in Uganda’s HIV prevention efforts.
In 2023, Uganda recorded 38,000 new HIV infections with almost half of new infections among adolescents and young people. The prevalence of new infections remains higher among females, with adolescent girls representing 80% of new infections among young people, highlighting the urgent need for targeted interventions.
Long-acting Injectable ART (LAI-ART) and Experiences.
Long-injectable antiretroviral treatment is a bi-monthly intramuscular treatment that combines cabotegravir and rilpivirine. It offers an alternative to daily oral medication.
Full story here (By Aaron Ainomugisha – Be In The Know
